Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.